PIRS Pieris Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PIRS

Price (delayed)

$11.88

Market cap

$14.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$21.6

Enterprise value

-$2.7M

Pieris Pharmaceuticals Inc.is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Its pipeline includes inhalable Anticalin ...

Highlights
The debt has shrunk by 100% QoQ and by 100% YoY
Pieris Pharmaceuticals's quick ratio has soared by 54% from the previous quarter and by 37% YoY
The company's gross profit has surged by 65% YoY but it fell by 10% QoQ
The revenue has soared by 65% YoY but it has contracted by 10% from the previous quarter
Pieris Pharmaceuticals's equity has decreased by 12% QoQ and by 4.2% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.pieris.com
Peers: CSBR GILD

Key stats

What are the main financial stats of PIRS
Market
Shares outstanding
1.24M
Market cap
$14.69M
Enterprise value
-$2.7M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.55
Price to sales (P/S)
0.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.06
Earnings
Revenue
$42.81M
EBIT
-$24.54M
EBITDA
-$22.76M
Free cash flow
-$53.99M
Per share
EPS
-$21.6
Free cash flow per share
-$47.96
Book value per share
$21.66
Revenue per share
$38.03
TBVPS
$34.36
Balance sheet
Total assets
$38.68M
Total liabilities
$11.92M
Debt
$0
Equity
$26.76M
Working capital
$26.76M
Liquidity
Debt to equity
0
Current ratio
3.24
Quick ratio
2.45
Net debt/EBITDA
0.76
Margins
EBITDA margin
-53.2%
Gross margin
100%
Net margin
-57.3%
Operating margin
-69.5%
Efficiency
Return on assets
-36.7%
Return on equity
-86.7%
Return on invested capital
-191.5%
Return on capital employed
-91.7%
Return on sales
-57.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PIRS stock price

How has the Pieris Pharmaceuticals stock price performed over time
Intraday
-1.33%
1 week
7,325%
1 month
5,840%
1 year
1,265.52%
YTD
6,500%
QTD
6,500%

Financial performance

How have Pieris Pharmaceuticals's revenue and profit performed over time
Revenue
$42.81M
Gross profit
$42.81M
Operating income
-$29.76M
Net income
-$24.54M
Gross margin
100%
Net margin
-57.3%
The company's gross profit has surged by 65% YoY but it fell by 10% QoQ
The revenue has soared by 65% YoY but it has contracted by 10% from the previous quarter
PIRS's operating margin has surged by 59% year-on-year and by 11% since the previous quarter
The net margin has soared by 55% YoY and by 3.4% QoQ

Growth

What is Pieris Pharmaceuticals's growth rate over time

Valuation

What is Pieris Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.55
P/S
0.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.06
The EPS has grown by 40% YoY and by 23% from the previous quarter
PIRS's P/B is 87% below its 5-year quarterly average of 4.1 and 68% below its last 4 quarters average of 1.7
Pieris Pharmaceuticals's equity has decreased by 12% QoQ and by 4.2% YoY
The stock's P/S is 94% below its 5-year quarterly average of 4.8 and 78% below its last 4 quarters average of 1.4
The revenue has soared by 65% YoY but it has contracted by 10% from the previous quarter

Efficiency

How efficient is Pieris Pharmaceuticals business performance
PIRS's return on invested capital has dropped by 81% year-on-year and by 28% since the previous quarter
The ROS has soared by 55% YoY and by 3.4% from the previous quarter
Pieris Pharmaceuticals's ROA has decreased by 23% YoY and by 6% from the previous quarter
PIRS's return on equity is up by 12% since the previous quarter but it is down by 5% year-on-year

Dividends

What is PIRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PIRS.

Financial health

How did Pieris Pharmaceuticals financials performed over time
PIRS's total liabilities has dropped by 82% year-on-year and by 59% since the previous quarter
PIRS's current ratio has soared by 61% year-on-year and by 58% since the previous quarter
The debt is 100% lower than the equity
The debt has shrunk by 100% QoQ and by 100% YoY
PIRS's debt to equity has plunged by 100% from the previous quarter and by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.